# An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07084584** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Galecto Biotech AB** · enrollment: 184 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** GB3226

## Key facts

- **NCT ID:** NCT07084584
- **Lead sponsor:** Galecto Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2029-06-10
- **Final completion:** 2029-10-10
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07084584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07084584, "An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07084584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*